MedTrace Logo

Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer

NCT03076567 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 440

Last updated 2020-02-25

No results posted yet for this study

Summary

Background:

Stomach cancer is common around the world. The US is a low-risk region. But the 5-year survival rate in the US is low. This is because the cancer is usually in a late stage by the time it is diagnosed. One way to detect it earlier is to screen many people with a procedure called endoscopy. But this may not be feasible in low-risk or developing countries. Researchers want to find a biomarker for early-stage disease to help them create an effective way of screening. DNA methylation is a chemical modification of DNA. It generates a signal for certain cancers, including stomach cancer. Researchers want to find a blood-based DNA methylation marker for stomach cancer.

Objective:

To study plasma DNA methylation as a potential biomarker for detection of stomach cancer.

Eligibility:

Participants from 2 studies already done in China

Design:

Researchers will use blood samples from participants in the 2 studies. The blood was collected in 1999/2000. They will use samples from some who developed stomach cancer between those years and 2006. The other samples will be from some who stayed cancer free in that time.

Participants already gave written informed consent.

Researchers will take DNA from the samples. They will look for methylation.

Conditions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Alisa M Goldstein, Ph.D. · National Cancer Institute (NCI)

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-09
Primary Completion
2020-02-14
Completion
2020-02-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03076567 on ClinicalTrials.gov